Skip to main content

Mersana Therapeutics, Inc. (MRSN)

NASDAQ: MRSN · IEX Real-Time Price · USD
6.07 -0.10 (-1.62%)
Dec 6, 2021 4:00 PM EST - Market closed
Market Cap436.50M
Revenue (ttm)44,000
Net Income (ttm)-149.92M
Shares Out71.91M
EPS (ttm)-2.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume729,870
Open6.27
Previous Close6.17
Day's Range6.02 - 6.31
52-Week Range6.02 - 29.09
Beta2.41
AnalystsStrong Buy
Price Target22.67 (+273.5%)
Earnings DateNov 9, 2021

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also dev...

IndustryBiotechnology
IPO DateJun 28, 2017
CEOAnna Protopapas
Employees110
Stock ExchangeNASDAQ
Ticker SymbolMRSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MRSN stock is "Strong Buy." The 12-month stock price forecast is 22.67, which is an increase of 273.48% from the latest price.

Price Target
$22.67
(273.48% upside)
Analyst Consensus: Strong Buy

News

Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B

Synaffix B.V. has expanded its license agreement with Mersana Therapeutics Inc (NASDAQ: MRSN) for antibody-drug conjugates (ADCs) targeting cancers.

6 days ago - Benzinga

Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

1 week ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -8.62% and 10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

3 weeks ago - Zacks Investment Research

Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

3 weeks ago - GlobeNewsWire

Earnings Preview: Mersana Therapeutics, Inc. (MRSN) Q3 Earnings Expected to Decline

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference.

1 month ago - Benzinga

Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agoni...

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual I...

CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

2 months ago - GlobeNewsWire

New Strong Sell Stocks for September 14th

ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.

Other symbols:ATRFTAIHGENLMB
2 months ago - Zacks Investment Research

Why Are Mersana Therapeutics Shares Trading Lower On Friday?

Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Rilsod...

2 months ago - Benzinga

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

2 months ago - GlobeNewsWire

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

3 months ago - GlobeNewsWire

Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

4 months ago - GlobeNewsWire

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

4 months ago - GlobeNewsWire

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sen...

UPGRADE umbrella study designed to evaluate UpRi in combination with other therapies, starting with carboplatin UPGRADE umbrella study designed to evaluate UpRi in combination with other therapies, star...

4 months ago - GlobeNewsWire

New Strong Sell Stocks for May 28th

ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

Other symbols:ACETFURYKRYSNBEV
6 months ago - Zacks Investment Research

Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

6 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st...

6 months ago - Zacks Investment Research

Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer - Ended first quarter of 2021 with $228 million in cash

6 months ago - GlobeNewsWire

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

7 months ago - GlobeNewsWire

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Vi...

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

7 months ago - GlobeNewsWire

Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients

Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will evalu...

7 months ago - Benzinga

Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and ...

Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET

7 months ago - GlobeNewsWire

Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant O...

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

7 months ago - GlobeNewsWire